Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sanjay Patel

Internal Medicine Bloomingdale, IL Medical Doctor

NPI 1235178831 CMS profile 56367

473 W Army Trail Rd Ste 106, Bloomingdale, IL 60108

Open in the dashboard

General payments

$4,252

207 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sanjay Patel of Bloomingdale, IL is reported in the CMS Open Payments database as having received $4,252 across 207 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $310 17
2024 General $652 39
2023 General $377 18
2022 General $560 31
2021 General $390 22
2020 General $178 11
2019 General $1,785 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sanjay Patel
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sanjay Patel were reported at $310. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sanjay Patel Internal Medicine median Middle half National median
2019 $1,785 $159 $48–$570 $163
2020 $178 $119 $33–$402 $114
2021 $390 $135 $37–$521 $132
2022 $560 $141 $42–$496 $149
2023 $377 $149 $45–$519 $160
2024 $652 $154 $47–$537 $164
2025 $310 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $939 56 payments
  2. Genzyme Corporation $700 1 payment
  3. Lilly USA, LLC $697 44 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $494 24 payments
  5. AstraZeneca Pharmaceuticals LP $399 25 payments
  6. Merck Sharp & Dohme Corporation $281 16 payments
  7. Janssen Pharmaceuticals, Inc $110 6 payments
  8. Pfizer Inc. $88 4 payments
  9. Amgen Inc. $86 5 payments
  10. Novartis Pharmaceuticals Corporation $84 6 payments
  11. Other $373 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,552 206 payments
  2. Grant $700 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $708 52 payments
  2. RYBELSUS $677 37 payments
  3. JARDIANCE Diabetes $450 28 payments
  4. JARDIANCE Diabetes $339 17 payments
  5. TRULICITY $322 20 payments
  6. STEGLATRO $281 16 payments
  7. ZEPBOUND $198 14 payments
  8. FARXIGA $197 12 payments
  9. JANUVIA $166 13 payments
  10. BASAGLAR $147 8 payments
  11. Other $2,051 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 85 drugs

Part D claims

6,828

Median for Internal Medicine: 777

Drug cost

$678,046

Median for Internal Medicine: $73,373

Branded share of claims

16.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 170 $183,732
Januvia Sitagliptin Phosphate Brand 150 $171,184
Rybelsus Semaglutide Brand 72 $113,034
Eliquis Apixaban Brand 43 $61,226
Tradjenta Linagliptin Brand 35 $24,878
Farxiga Dapagliflozin Propanediol Brand 21 $19,251
Linzess Linaclotide Brand 32 $17,575
Ozempic Semaglutide Brand 12 $10,988
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $10,534
Breo Ellipta Fluticasone/Vilanterol Brand 18 $8,450

The 10 drugs with the highest cost, of 85 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$127,473

Of which drugs: $2,543

Medicare patients

225

Average age 77

Services billed

2,365

126 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 51%
Arthritis 33%
Ischemic heart disease 28%
Chronic kidney disease 18%
Heart failure 16%
Osteoporosis 16%
Cancer 9%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 11 11 $1,439

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $84
  • Boehringer Ingelheim Pharmaceuticals, Inc. $47
$132 170 —
ZEPBOUND
  • Lilly USA, LLC $75
$75 — —
RYBELSUS
  • Novo Nordisk Inc $54
$54 72 —
Ozempic
  • Novo Nordisk Inc $54
$54 12 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record